A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Roche logo

Roche

Status and phase

Terminated
Phase 3

Conditions

Alzheimer Disease

Treatments

Drug: Gantenerumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT04374253
WN42171
2020-000766-42 (EudraCT Number)

Details and patient eligibility

About

This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.

Full description

Participants who were in the active arm in the double blind part and those who have completed OLE part in the parent study, will continue receive open-label gantenerumab 510 mg sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme as in the parent study before receiving target dose of open label gantenerumab.

Enrollment

1,379 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did not discontinue study drug early
  • The participant should be capable of completing assessments either alone or with the help of the caregiver
  • Availability of a person (referred to as the "caregiver")
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception methods with a failure rate of <1% per year (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the treatment period and for at least 16 weeks after the final dose of gantenerumab
  • Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug

Exclusion criteria

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within at least 16 weeks after the final dose of study drug
  • Prematurely discontinued from Study WN29922 or WN39658
  • Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
  • Received any investigational treatment other than gantenerumab during or since completion of Study WN29922 or WN39658, either its double-blind or OLE part
  • Evidence of disseminated leptomeningeal hemosiderosis
  • Evidence of intracerebral macrohemorrhage
  • Use of prohibited medication
  • Evidence of ARIA-E on the last MRI scan report in Study WN29922 or WN39658, either its double-blind or OLE part

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

1,379 participants in 2 patient groups

Group 1
Experimental group
Description:
Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 116 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
Treatment:
Drug: Gantenerumab
Group 2
Experimental group
Description:
Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
Treatment:
Drug: Gantenerumab

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems